NO984564D0 - FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister - Google Patents

FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister

Info

Publication number
NO984564D0
NO984564D0 NO984564A NO984564A NO984564D0 NO 984564 D0 NO984564 D0 NO 984564D0 NO 984564 A NO984564 A NO 984564A NO 984564 A NO984564 A NO 984564A NO 984564 D0 NO984564 D0 NO 984564D0
Authority
NO
Norway
Prior art keywords
heart failure
treating heart
endothelin antagonists
blooded animal
warm blooded
Prior art date
Application number
NO984564A
Other languages
English (en)
Other versions
NO984564L (no
Inventor
Jr Joseph J Lynch
You-Tang Shen
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of NO984564D0 publication Critical patent/NO984564D0/no
Publication of NO984564L publication Critical patent/NO984564L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
NO984564A 1996-04-04 1998-09-30 FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister NO984564L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1488296P 1996-04-04 1996-04-04
PCT/US1997/003737 WO1997037665A1 (en) 1996-04-04 1997-03-19 Method of treating heart failure with endothelin antagonists

Publications (2)

Publication Number Publication Date
NO984564D0 true NO984564D0 (no) 1998-09-30
NO984564L NO984564L (no) 1998-12-04

Family

ID=21768326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984564A NO984564L (no) 1996-04-04 1998-09-30 FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister

Country Status (25)

Country Link
US (3) US5834483A (no)
EP (1) EP0906108B1 (no)
JP (2) JP3345891B2 (no)
KR (1) KR20000005178A (no)
CN (1) CN1215335A (no)
AT (1) ATE297739T1 (no)
AU (1) AU723351B2 (no)
BG (1) BG102716A (no)
BR (1) BR9708525A (no)
CA (1) CA2249330C (no)
CZ (1) CZ296098A3 (no)
DE (1) DE69733557T2 (no)
EA (1) EA003587B1 (no)
EE (1) EE9800315A (no)
ES (1) ES2241047T3 (no)
HU (1) HUP9903893A3 (no)
IL (1) IL126175A (no)
IS (1) IS4847A (no)
NO (1) NO984564L (no)
NZ (1) NZ331789A (no)
PL (1) PL329077A1 (no)
SK (1) SK130098A3 (no)
TR (1) TR199801988T2 (no)
UA (1) UA50761C2 (no)
WO (1) WO1997037665A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003587B1 (ru) 1996-04-04 2003-06-26 Баниу Фармасьютикал Ко., Лтд. Способ предупреждения и/или лечения сердечной недостаточности и дисфункции желудочков антагонистами эндотелина
JPH11514676A (ja) * 1996-08-09 1999-12-14 メルク エンド カンパニー インコーポレーテッド 立体選択的脱酸素化反応
US6413979B1 (en) 1998-01-21 2002-07-02 Banyu Pharmaceutical Co., Ltd. Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JPWO2004060885A1 (ja) * 2002-12-27 2006-05-11 株式会社カネカ 光学活性２−チオメチル−３−フェニルプロピオン酸誘導体およびその合成中間体の製造法
EP2839832A3 (en) 2003-11-17 2015-06-24 Novartis AG Use of dipeptidyl peptidase IV inhibitors
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
KR20070006774A (ko) 2004-03-17 2007-01-11 노파르티스 아게 치료에서 레닌 억제제의 용도
EP1894582A1 (en) 2005-06-24 2008-03-05 Tokyo Medical and Dental University Method for control of drug elution rate and composition for coating of drug-eluting stent
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
CA2169737C (en) * 1993-08-18 2003-04-15 Kiyofumi Ishikawa Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
EA003587B1 (ru) * 1996-04-04 2003-06-26 Баниу Фармасьютикал Ко., Лтд. Способ предупреждения и/или лечения сердечной недостаточности и дисфункции желудочков антагонистами эндотелина

Also Published As

Publication number Publication date
HUP9903893A3 (en) 2001-05-28
UA50761C2 (uk) 2002-11-15
US6380195B1 (en) 2002-04-30
JP3345891B2 (ja) 2002-11-18
IS4847A (is) 1998-09-15
EE9800315A (et) 1999-06-15
IL126175A0 (en) 1999-05-09
ATE297739T1 (de) 2005-07-15
US6087360A (en) 2000-07-11
IL126175A (en) 2003-05-29
AU723351B2 (en) 2000-08-24
HUP9903893A2 (hu) 2001-04-28
US5834483A (en) 1998-11-10
TR199801988T2 (xx) 2000-08-21
ES2241047T3 (es) 2005-10-16
DE69733557T2 (de) 2005-11-03
EA199800889A1 (ru) 1999-04-29
CN1215335A (zh) 1999-04-28
BG102716A (en) 1999-09-30
CZ296098A3 (cs) 1999-06-16
NZ331789A (en) 2000-05-26
SK130098A3 (en) 1999-05-07
JP2000510824A (ja) 2000-08-22
BR9708525A (pt) 1999-08-03
KR20000005178A (ko) 2000-01-25
EA003587B1 (ru) 2003-06-26
CA2249330A1 (en) 1997-10-16
EP0906108B1 (en) 2005-06-15
CA2249330C (en) 2005-08-09
EP0906108A1 (en) 1999-04-07
NO984564L (no) 1998-12-04
AU2202597A (en) 1997-10-29
JP2002220337A (ja) 2002-08-09
EP0906108A4 (en) 2000-12-06
WO1997037665A1 (en) 1997-10-16
PL329077A1 (en) 1999-03-15
DE69733557D1 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
CY1110282T1 (el) Ενωσεις για την αγωγη της απωλειας βαρους
HK1044333A1 (zh) 趨化因子受體拮抗劑及其使用方法
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
NO984564D0 (no) FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
EA200101116A1 (ru) Способ лечения фиброза с помощью альфа-4-субъединицы антагониста интегрина
NO20003313D0 (no) Terapeutiske midler
EA199900431A1 (ru) Способ профилактики рака молочной железы
DK1294379T3 (da) En hidtil ukendt anvendelse af deferipron
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
IL120303A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
ATE289506T1 (de) Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
TR200103704T2 (tr) Terapötik ajanlar
EA200100041A1 (ru) Способ лечения
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
EA200101159A1 (ru) Произодное аминотетралина для терапии сердечно-сосудистых заболеваний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application